TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharmaxis Ltd ( (AU:SNT) ) has shared an announcement.
Pharmaxis Ltd has announced positive final Phase 2a data for its drug candidate amsulostat, which is being developed for the treatment of myelofibrosis. This development confirms amsulostat’s competitive profile in the market, potentially enhancing Pharmaxis’s positioning within the pharmaceutical industry and offering promising implications for stakeholders involved in the treatment of myelofibrosis.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 4,424,039
Technical Sentiment Signal: Sell
Current Market Cap: A$40.81M
Learn more about SNT stock on TipRanks’ Stock Analysis page.